However, it is still unknown whether antagonising PTBP1 in clinical treatment can improve drug therapeutic efficacy and whether drug development targeting PTBP1 can improve patients' prognosis, and it would significantly improve tumour therapeutic efficacy if the impact of PTBP1 in different tumour drug therapies can be clarified. The gene discussed is PTBP1; the disease is neoplasm.